Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2647 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-04-04 (tradingview.com)
Hope for Vietnam deal drives shoe and fashion shares- news
The stock exchange ticker follows important price movements on the international financial markets and their causes: 6.35 p.m.-The shares of US shoe and fashion companies turn into the plus after President Donald Trump has declared that Vietnam's president has a reduction in tariffs to US imports ...
Read more
2025-02-12 (endpts.com)
Biogen gets $250M in Royalty Pharma deal for Phase 3 lupus program
Biogen is turning to Royalty Pharma for some cash in exchange for rights to a lupus program, the companies announced Wednesday. The two have agreed on a deal for litifilimab ...
Read more
2025-02-03 (openpr.com)
Tardive Dyskinesia Treatment Market Report Analysis and Research Studies, Comprehensive Insights and Key Players - Pfizer Inc., Biogen, Novartis AG.
Press release - DataM Intelligence 4Market Research - Tardive Dyskinesia Treatment Market Report Analysis and Research Studies, Comprehensive Insights and Key Players - Pfizer Inc., Biogen, Novartis AG. - published on openPR.com
Read more
2025-01-16 (openpr.com)
Drugs for Central Nervous System Diseases Market Size, Future Trends And Forecast to 2033 Biogen, Alkermes, Astrazeneca, Pfizer
Press release - FUTURE MARKET REPORT - Drugs for Central Nervous System Diseases Market Size, Future Trends And Forecast to 2033 Biogen, Alkermes, Astrazeneca, Pfizer - published on openPR.com
Read more
2025-01-14 (benzinga.com)
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge - Abercrombie & Fitch (NYSE:ANF), Biogen (NASDAQ:BIIB) -
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Monday.
Read more
2025-01-13 (aktiencheck.de)
Biogen share: Updates on the current market price () | .de
Biogen share: Updates on the current market price () | aktiencheck.de
Read more
2025-01-12 (defenseworld.net)
Wells Fargo & Company Issues Pessimistic Forecast for Biogen (NASDAQ:BIIB) Stock Price -
Read Wells Fargo & Company Issues Pessimistic Forecast for Biogen (NASDAQ:BIIB) Stock Price at Defense World
Read more
2025-01-10 (bostonglobe.com)
Alzheimer’s drugs eyed as next big obesity-like opportunity - The Boston Globe
Companies including Biogen and Eli Lilly & Co. have spent billions of dollars on developing potential treatments, while others including Novo Nordisk A/S and Roche AG are also investigating the brain-destroying disease.
Read more
2025-01-07 (100x100musica.es)
Drugs for Solid Tumors Market Size, Envisioning Market Evolution (2024-2034) – 100×100 Música
MR Accuracy Reports introduces new research on Drugs for Solid Tumors Market covering the micro level of analysis by competitors and key business segments. The Drugs for Solid Tumors explores a comprehensive study of various segments like opportunities, size, development, innovation, sales, and overall growth of major players. The research is carried out on primary and secondary statistics sources and it consists of both qualitative and quantitative detailing. Some of the major key players profiled in the study are Prudential
Read more